Table 7.
Clinical Characteristics in PAD Population (STUDY 3, n=309)
| Independent Variable | % |
|---|---|
| Gender (male/female) | 60.5/39.5 |
| Smoking | 60.5 |
| Diabetes mellitus | 14.2 |
| Hypertension | 49.5 |
| Previous ischemic cerebral event | 9.7 |
| Previous acute myocardial infarction | 13.3 |
| Previous or present angina pectoris | 23.0 |
| Chronical obstructive pulmonary disease | 9.9 |
| Hyperlipidaemia | 37.7 |
| Use of low‐dose aspirin | 57.8 |
| Use of warfarin | 5.0 |
| Use of beta‐blocker | 18.8 |
| Use of ACE inhibitor | 18.1 |
| Use of calcium blocker | 21.6 |
| Use of statin | 19.9 |
| Chronical critical ischemia | 50.9 |
| Median (IQR) | |
| Age, y | 67.1 (62.1 to 72.1) |
| Systolic blood pressure, mm Hg | 144 (130 to 160) |
| Diastolic blood pressure, mm Hg | 78 (70 to 85) |
| Pulse pressure, mm Hg | 65 (55 to 80) |
| Height, m | 1.70 (1.65 to 1.75) |
| Weight, kg | 71.5 (60.0 to 80.0) |
| Body mass index, kg/m2 | 24.5 (22.0 to 27.5) |
| Max. walking distance, m | 100 (11.5 to 200) |
| Lowest ankle brachial blood pressure index | 0.78 (0.55 to 1.00) |
| Total cholesterol | 5.20 (4.40 to 6.10) |
| hs‐CRP | 11.0 (3.27 to 39.7) |
| S‐Galectin 3 | 4.75 (2.47 to 14.7) |
ACE indicates angiotensin‐converting enzyme; hs‐CRP, high‐sensitivity C‐reactive protein; PAD, peripheral arterial disease.